Sutandyo Noorwati, Kosasih Agus Susanto, Sari Resti Mulya, Setiawan Lyana, Rinaldi Ikhwan, Maskito Veronika Juanita, Prayitno Yuniar Harris
Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.
Department of Hematology and Medical Oncology, Dharmais National Cancer Center Hospital, Jakarta, Indonesia.
F1000Res. 2024 Mar 8;13:167. doi: 10.12688/f1000research.143170.1. eCollection 2024.
Cytogenetics is a fundamental examination in the course and management of myelodysplastic syndrome (MDS) since it is widely used as a diagnostic and prognostic indicator for the disease. Some cytogenetic profiles are associated with a higher risk of acute myeloid leukemia (AML) transformation. This is the first study to evaluate the cytogenetic profile of Indonesian patients with MDS.
This prospective cohort study was conducted at the Cancer Center and several other referral hospitals. Patients with primary MDS aged >18 years were included in the study. Clinical examination, peripheral blood smear, and bone marrow aspiration were performed, followed by cytogenetic examination. The results were further categorized into revised international prognostic scoring system (IPSS-R) scores, and cytogenetic profiles were descriptively presented. Patients were followed up for one year to evaluate AML transformation.
A total of 28 MDS patients, aged 66±12 years, were included in this study. The majority of the patients were male (n=17;60.7%), aged 65 years or above (n=19;67.9%), diagnosed with MDS-MLD (n=14;50%), and had an intermediate cytogenetic group (n=4;14.3%). The IPSS-R score was high in 6 (21.4%) patients and very high risk in 3 (10.7%) patients. During one-year follow-up, AML transformation occurred in 3 (10.7%) patients, and 10 (35.7%) patients ceased. Monosomy 7 was observed in 6 (21.4%) patients but in one metaphase each. Deletion of chromosome 5 (del(5)(q31)), del (16)(q21.1), and del (16)(q11.2) were found in a male patient with MDS-EB1.
Monosomy 7 and deletion of chromosome 5 have been identified in Indonesian patients with MDS. MDS-EB has the highest risk of AML transformation.
细胞遗传学是骨髓增生异常综合征(MDS)病程及管理中的一项基本检查,因为它被广泛用作该疾病的诊断和预后指标。一些细胞遗传学特征与急性髓系白血病(AML)转化的较高风险相关。这是第一项评估印度尼西亚MDS患者细胞遗传学特征的研究。
这项前瞻性队列研究在癌症中心和其他几家转诊医院进行。纳入年龄>18岁的原发性MDS患者。进行临床检查、外周血涂片和骨髓穿刺,随后进行细胞遗传学检查。结果进一步分类为修订的国际预后评分系统(IPSS-R)评分,并对细胞遗传学特征进行描述性呈现。对患者进行一年的随访以评估AML转化情况。
本研究共纳入28例MDS患者,年龄为66±12岁。大多数患者为男性(n = 17;60.7%),年龄在65岁及以上(n = 19;67.9%),诊断为MDS-MLD(n = 14;50%),且细胞遗传学分组为中间组(n = 4;14.3%)。6例(21.4%)患者的IPSS-R评分为高危,3例(10.7%)患者为极高危。在一年的随访期间,3例(10.7%)患者发生AML转化,10例(35.7%)患者病情缓解。6例(21.4%)患者观察到7号染色体单体,但每个中期仅观察到1例。在1例MDS-EB1男性患者中发现了5号染色体缺失(del(5)(q31))、16号染色体缺失(del(16)(q21.1))和16号染色体缺失(del(16)(q11.2))。
在印度尼西亚MDS患者中已鉴定出7号染色体单体和5号染色体缺失。MDS-EB发生AML转化的风险最高。